GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHaleon Regulatory News (HLN)

Share Price Information for Haleon (HLN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 330.60
Bid: 330.50
Ask: 330.70
Change: 2.80 (0.85%)
Spread: 0.20 (0.061%)
Open: 329.30
High: 331.80
Low: 328.80
Prev. Close: 327.80
HLN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Haleon 2024 Annual General Meeting

8 May 2024 17:15

RNS Number : 6797N
Haleon PLC
08 May 2024
 

 

 

Haleon plc: Results of Haleon 2024 Annual General Meeting

 

8 May 2024: Haleon plc (the "Company") (LSE/NYSE: HLN) announces that the following resolutions were decided by poll vote at the Company's 2024 Annual General Meeting ("AGM") which was held today.

 

Resolutions 19, 20, 21, 22 and 23 were passed as special resolutions; all other resolutions were passed as ordinary resolutions. Full text of the resolutions is contained in the Company's Notice of AGM, which is available at www.haleon.com.

 

Haleon plc - Poll Results

 

Resolution

Votes for

For (% of shares voted)

Votes against

Against (% of shares voted)

Total votes cast (excluding withheld)

% of issued share capital voted1

Votes withheld2

1

To receive the Annual Report & Accounts

7,919,982,698

99.98

1,912,695

0.02

7,921,895,393

86.75

27,443,703

2

To approve the Directors' Remuneration Report

7,586,720,188

95.74

337,969,514

4.26

7,924,689,702

86.78

24,649,536

3

To declare a final dividend

7,925,111,048

99.98

1,306,988

0.02

7,926,418,036

86.80

22,921,018

4

To re-elect Sir Dave Lewis

7,776,694,667

98.12

148,882,400

1.88

7,925,577,067

86.79

23,760,986

5

To re-elect Brian McNamara

7,895,750,784

99.62

29,983,210

0.38

7,925,733,994

86.79

23,604,061

6

To re-elect Tobias Hestler

7,862,098,220

99.20

63,569,514

0.80

7,925,667,734

86.79

23,660,869

7

To re-elect Manvinder Singh (Vindi) Banga

7,850,438,949

99.05

75,078,917

0.95

7,925,517,866

86.79

23,816,186

8

To re-elect Marie-Anne Aymerich

7,875,097,674

99.36

50,511,000

0.64

7,925,608,674

86.79

23,729,379

9

To re-elect Tracy Clarke

7,811,967,620

98.57

113,662,811

1.43

7,925,630,431

86.79

23,707,622

10

To re-elect Dame Vivienne Cox

7,866,672,212

99.26

58,970,463

0.74

7,925,642,675

86.79

23,695,377

11

To re-elect Asmita Dubey

7,900,143,514

99.68

25,487,188

0.32

7,925,630,702

86.79

23,707,349

12

To re-elect Deirdre Mahlan

6,982,240,376

88.31

924,143,645

11.69

7,906,384,021

86.58

42,954,032

13

To re-elect David Denton

7,889,873,836

99.55

35,557,933

0.45

7,925,431,769

86.78

23,906,285

14

To re-elect Bryan Supran

7,890,428,132

99.56

35,117,662

0.44

7,925,545,794

86.79

23,791,864

15

To re-appoint KPMG LLP as auditor of the Company

7,909,270,829

99.79

16,746,573

0.21

7,926,017,402

86.79

23,320,243

16

To authorise the Audit & Risk Committee to determine the remuneration of the auditor

7,924,013,951

99.98

1,760,576

0.02

7,925,774,527

86.79

23,561,370

17

To authorise the Company to make political donations

7,860,827,630

99.42

45,956,705

0.58

7,906,784,335

86.58

42,553,903

18

To authorise the Directors to allot shares

7,674,156,770

96.83

250,966,046

3.17

7,925,122,816

86.78

24,216,236

19

General authority to disapply pre-emption rights

7,708,543,512

97.28

215,438,109

2.72

7,923,981,621

86.77

25,356,460

20

Additional authority to disapply pre-emption rights

7,612,018,804

96.06

311,981,315

3.94

7,924,000,119

86.77

25,336,232

21

To shorten the notice period for General Meetings

7,511,133,326

94.77

414,387,584

5.23

7,925,520,910

86.79

23,816,443

22

To authorise the Company to purchase its own shares

7,902,657,875

99.73

21,458,230

0.27

7,924,116,105

86.77

25,218,017

23

To authorise the Company to make off-market purchases of its own shares from Pfizer3

5,857,582,236

99.90

5,872,298

0.10

5,863,454,534

64.21

418,101,609

 

1 For the purposes of section 341 of the Companies Act 2006, Haleon plc's total issued share capital with voting rights as at 6.30pm on Friday 3 May 2024, being the time at which a shareholder had to be registered in the Company's register of members in order to attend and vote at the AGM, was 9,132,301,104.

2 A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

3 Pfizer Inc. did not vote any of the ordinary shares held in respect of Resolution 23.

 

As required by the Listing Rule 9.6.2R of the Financial Conduct Authority ("FCA"), copies of resolutions passed by the Company other than resolutions concerning ordinary business have been submitted to the FCA via the National Storage Mechanism and will shortly be available to the public for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

 

Amanda Mellor 

Company Secretary 

 

 

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGQVLFBZELBBBF
Date   Source Headline
31st May 20244:47 pmRNSDisposal of the ChapStick brand completed
23rd May 20245:15 pmRNSDirector/PDMR Shareholding
20th May 20242:45 pmRNSHolding(s) in Company
20th May 20242:15 pmRNSDirector/PDMR Shareholding
17th May 20245:30 pmRNSHaleon
8th May 20245:15 pmRNSResults of Haleon 2024 Annual General Meeting
7th May 20249:30 amRNSEMTN programme: publication of base prospectus
1st May 202411:10 amRNSDirectorate Change
1st May 20247:00 amRNSHaleon 2024 Q1 Trading Statement
24th Apr 20247:00 amRNSAppointment of Dawn Allen as CFO
12th Apr 202412:00 pmRNSNotice of Annual General Meeting (AGM)
3rd Apr 202411:30 amRNSDirector/PDMR Shareholding
2nd Apr 20249:15 amRNSTotal Voting Rights and Capital
22nd Mar 202411:30 amRNSHolding(s) in Company
21st Mar 20246:00 pmRNSHaleon
21st Mar 20244:38 pmRNSTotal Voting Rights and Capital
21st Mar 20244:05 pmRNSClosing of Secondary Global Offering by Pfizer
20th Mar 20248:39 amRNSFinal prospectus supplement filed with the SEC
19th Mar 20247:00 amRNSPricing and upsize of Secondary Global Offering
18th Mar 202411:00 amRNSPreliminary prospectus supplement filed with SEC
18th Mar 20247:00 amRNSProposed Secondary Global Offering by Pfizer Inc.
15th Mar 20243:00 pmRNSPublication of Annual Report and Form 20-F 2023
14th Mar 20244:20 pmRNSDirector/PDMR Shareholding
12th Mar 20243:30 pmRNSDirector/PDMR Shareholding
5th Mar 20242:30 pmRNSDirector/PDMR Shareholding
29th Feb 20247:00 amRNSHaleon Preliminary 2023 Full Year Results
2nd Feb 20242:15 pmRNSDirector Declaration
25th Jan 20247:00 amRNSHaleon to sell ChapStick
18th Jan 20245:00 pmRNSHolding(s) in Company
17th Jan 20246:00 pmRNSHaleon
11th Jan 20241:00 pmRNSDirector/PDMR Shareholding
19th Dec 20231:00 pmRNSDirector/PDMR Shareholding
13th Dec 202310:30 amRNSDirector/PDMR Shareholding
10th Nov 20231:00 pmRNSDirector/PDMR Shareholding
2nd Nov 20237:00 amRNSHaleon 2023 Q3 Trading Statement
13th Oct 20233:30 pmRNSDirector/PDMR Shareholding
11th Oct 20233:00 pmRNSDirector/PDMR Shareholding
10th Oct 202311:00 amRNSHolding(s) in Company
6th Oct 20236:00 pmRNSHaleon
6th Oct 20232:30 pmRNSDirector/PDMR Shareholding
28th Sep 202311:00 amRNSDirector Declaration
13th Sep 20239:30 amRNSDirector/PDMR Shareholding
10th Aug 20231:00 pmRNSDirector/PDMR Shareholding
2nd Aug 20237:00 amRNSHaleon Half Year Results 2023
13th Jul 202311:00 amRNSDirector/PDMR Shareholding
12th Jun 20231:00 pmRNSDirector/PDMR Shareholding
16th May 20232:00 pmRNSHolding(s) in Company
16th May 20232:00 pmRNSHolding(s) in Company
12th May 20235:30 pmRNSHaleon
12th May 20234:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.